

event rates. Even when the study is completed, whether there will be adequate statistical power to reach a definite conclusion about cardiovascular safety is uncertain.

The RECORD trial was designed as a noninferiority trial with a noninferiority margin of 20% (i.e., an upper bound of the 95% confidence interval exceeding 1.20 fails to establish noninferiority). The upper bound of 1.32 found in the interim analysis indicates that the noninferiority of rosiglitazone, as compared with non-rosiglitazone regimens, has not been established. In short, this means that there is continued uncertainty about the cardiovascular safety of rosiglitazone. Furthermore, the upper bound of 1.81 for the myocardial infarction end point indicates that the RECORD data are not discordant with the results of the meta-analysis by Nissen and Wolski, given that the 95% confidence intervals in the two studies overlap extensively.

The clinical impact of these data needs to be clarified. To do so, we asked a diabetologist, a cardiovascular epidemiologist, and a drug-safety expert to give their interpretations, which can be found in the accompanying editorials.^{5,6} Both editorials express uncertainty about the safety of rosiglitazone.

When a drug is approved for marketing, its full safety profile cannot be known, and the data from the two studies we have published^{1,4} represent a

clear example of how difficult it can be to determine drug safety. In this age of freely available information, drugs cannot easily be parsed into “safe” and “unsafe” categories. Instead, there will be shades of safety that must be graded against shades of efficacy. As new data about the safety of an approved drug become available, they should not be suppressed. On the contrary, they should be reported to health care professionals, patients, and participants in ongoing clinical trials, even if that means creating uncertainty about the safety of a drug. Although there may be uncertainty about a drug’s safety, there should be no uncertainty about the need for open and honest disclosure.

This article (10.1056/NEJMe078118) was published at www.nejm.org on June 5, 2007.

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med* 2007;356:2457-71.
 2. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. *N Engl J Med* 2007;356:2522-4.
 3. GlaxoSmithKline. Study no. ZM2005/00181/01: Avandia Cardiovascular Event Modeling Project. (Accessed June 14, 2007, at http://ctr.gsk.co.uk/Summary/Rosiglitazone/III_CVmodeling.pdf.)
 4. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes — an interim analysis. *N Engl J Med* 2007;357:28-38.
 5. Nathan DM. Rosiglitazone and cardiotoxicity — weighing the evidence. *N Engl J Med* 2007;357:64-6.
 6. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. *N Engl J Med* 2007;357:67-9.
- Copyright © 2007 Massachusetts Medical Society.

Rosiglitazone and Cardiotoxicity — Weighing the Evidence

David M. Nathan, M.D.

The recently published meta-analysis by Nissen and Wolski,¹ which suggested a significant increase in the risk of myocardial infarction associated with treatment with rosiglitazone (Avandia) and an increase of similar magnitude, albeit nonsignificant, in the risk of death from cardiovascular causes, has created a furor in the press and a quandary for physicians and their patients. Given the vagaries of meta-analyses in general and of this meta-analysis in particular — owing to the absence of primary or time-to-event data, as acknowledged both in the article and in the accompanying editorial² — clinicians have been

left uncertain as to whether rosiglitazone should still be considered for the treatment of type 2 diabetes. Because millions of patients with diabetes are being treated with rosiglitazone worldwide, the answer to this question has major implications.

With the goal of providing the “current totality of evidence,” Home and colleagues report, in this issue of the *Journal*, an unscheduled interim analysis from the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes, or RECORD, study (NCT00379769) — a multicenter, drug-company-sponsored,

open-label, noninferiority trial.³ Whereas the 42 trials included in the published meta-analysis were generally directed at studying glycemia and were not designed or powered to study potential adverse events such as cardiovascular disease, the RECORD trial was specifically designed to measure the effects on cardiovascular outcomes of treatment with rosiglitazone combined with metformin or sulfonylurea, as compared with those of treatment with metformin combined with sulfonylurea. The primary end point of the RECORD trial consists of an aggregate of time to first hospitalization for a cardiovascular event or death from cardiovascular causes.⁴ According to the RECORD investigators who designed the study, including employees of the drug's manufacturer, GlaxoSmithKline, the RECORD trial was directed at determining whether the "promising" impact of thiazolidinediones on insulin sensitivity and cardiovascular risk factors would translate into an improvement in cardiovascular clinical outcomes.⁴ In addition, the investigators wanted to "address concerns over cardiac failure; confirm that the better outcomes associated with improved glucose control, as reported by the UKPDS [the United Kingdom Prospective Diabetes Study], are applicable to this group of drugs; and allay concerns based on LDL [low-density lipoprotein] cholesterol concentrations rather than LDL particle atherogenicity." In my opinion, several of these goals seem to reflect a company-oriented posture regarding rosiglitazone, rather than a neutral scientific inquiry.

As noted, the RECORD trial was designed specifically to study the cardiovascular effects of treatment with rosiglitazone, and results from a well-designed, adequately powered clinical trial are usually more reliable than results from a meta-analysis. Unfortunately, this interim analysis, performed after a mean of 3.75 years (about 60% of the planned 6-year duration of the study), fails to provide exculpatory evidence. First, the unexpectedly low rate of events (only about 2.5% per year, as compared with the 11% per year that went into the sample-size calculation) and a higher-than-expected rate of loss to follow-up (almost 3% per year, as compared with a projected 2% per year) have left RECORD extremely underpowered for the primary outcome. Second, the choice of the active comparator, metformin plus sulfonylurea, is problematic. In a substudy of the UKPDS,

the addition of metformin to treatment with sulfonylurea was associated with a 96% increase in diabetes-related mortality ($P=0.039$) among patients randomly assigned to receive this treatment.⁵ Although this result was described by the UKPDS investigators as a possible "play of chance," it has never been adequately explained or explored. The results of the RECORD trial should be interpreted with this UKPDS finding in mind. Specifically, any difference or lack of difference in outcomes between the treatment groups may be predicated on a potential adverse effect of metformin plus sulfonylurea.

With these caveats in mind, the results of this underpowered interim analysis suggest a possible adverse effect of treatment with rosiglitazone on the primary outcome, rather than the benefit that was hypothesized. Although the only outcome that was significantly more frequent with rosiglitazone was the risk of congestive heart failure, which more than doubled, Figure 2 in the article by Home et al.³ reveals a separation between the treatment groups for the adjudicated and total primary outcomes that, with more time and more events, could become significant. Considering the low power of the study and the trend for more adverse cardiovascular outcomes in the rosiglitazone-treated group, it is highly unlikely that the study will ever establish a cardiovascular benefit for rosiglitazone.

The interim results of the RECORD trial do not provide any assurance of the safety of treatment with rosiglitazone. Neither the original meta-analysis, with an odds ratio for myocardial infarction of 1.43 (95% confidence interval [CI], 1.03 to 1.98),¹ nor the meta-analysis performed independently by GlaxoSmithKline (odds ratio, 1.31; 95% CI, 1.01 to 1.70),⁶ nor the current finding, with a hazard ratio of 1.08 (95% CI, 0.89 to 1.31)³ can be considered conclusive. In the aggregate, however, these analyses support a concern regarding the safety of rosiglitazone.

With the continuing uncertainty regarding the safety of treatment with rosiglitazone, what should physicians and patients do? It is important to remember that there are now nine classes of antidiabetic medications available, including several older medications that are relatively efficacious in lowering glycated hemoglobin levels and are less expensive than the thiazolidinediones.⁷ Each class has a unique set of side effects

and associated adverse events. Controlling glycemia by keeping glycosylated hemoglobin levels as close to the nondiabetic range as possible has been established as the primary goal of these medications, given the salutary results of intensive therapy as demonstrated in high-quality clinical trials.^{5,8} The results of clinical trials of the effects of glycemic control on microvascular complications in type 1 and type 2 diabetes, combined with the results of studies in animal models, have supported the maintenance of lower glycosylated hemoglobin levels as advantageous, regardless of the means used to achieve that control. However, now that we are faced with evidence that specific medication regimens used to treat type 2 diabetes may have an adverse macrovascular effect independent of achieved levels of glycosylated hemoglobin, this premise may be challenged. Of note, a recently published analysis of the first 1122 participants in the RECORD trial studied for 18 months, using a noninferiority approach, showed that the glycemic control achieved did not differ significantly between the treatment groups.⁹

It is reasonable to ask whether physicians should feel comfortable using a drug that might have an 8% excess risk of severe cardiovascular disease or death from cardiovascular causes. Given the other choices of therapy available, including pioglitazone, which has limited clinical trial data suggesting a protective cardiovascular effect¹⁰ (albeit in a study that has been criticized for its design and its analysis), the answer should be no. Unless further studies can provide convincing assurance that treatment with rosiglitazone does not increase the risk of cardiovascular disease, the largely circumstantial evidence of the meta-analyses and the nonsignificant trend in the current report from the RECORD trial must be taken seriously. Physicians may find it difficult to explain to patients why they are starting treatment with a potentially dangerous drug when other choices with longer and better safety records are available. And although changing from a drug that is apparently working well to another medication may represent a challenge, the same safety concerns pertain. Whether ongoing stud-

ies for specific indications — such as reduction of restenosis after angioplasty and stent implantation, for which there is preliminary evidence of a benefit with rosiglitazone¹¹ — should continue will need to be considered individually, on the basis of potential risks and benefits. The jury may still be out with regard to the cardiotoxicity of rosiglitazone, but when it comes to patient safety, “first, do no harm” should outweigh any presumption of innocence.

Dr. Nathan reports receiving lecture fees from Pfizer, GlaxoSmithKline, and Novartis and grant support from Novo Nordisk and Sanofi-Aventis. No other potential conflict of interest relevant to this article was reported.

From the Diabetes Center at Massachusetts General Hospital, and Harvard Medical School, Boston.

This article (10.1056/NEJMe078117) was published at www.nejm.org on June 5, 2007.

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med* 2007;356:2457-71.
2. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. *N Engl J Med* 2007;356:2522-4.
3. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes — an interim analysis. *N Engl J Med* 2007;357:28-38.
4. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. *Diabetologia* 2005;48:1726-35.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;352:854-65. [Erratum, *Lancet* 1998;352:1558.]
6. GlaxoSmithKline. Study no. ZM2005/00181/01: Avandia Cardiovascular Event Modeling Project. (Accessed June 14, 2007, at http://ctr.gsk.co.uk/summary/Rosiglitazone/III_CVmodeling.pdf.)
7. Nathan DM. Finding new treatments for diabetes — how many, how fast . . . how good? *N Engl J Med* 2007;356:437-40.
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-86.
9. Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. *Diabet Med* 2007;24:626-34.
10. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005;366:1279-89.
11. Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. *Diabetes Care* 2004;27:2654-60.

Copyright © 2007 Massachusetts Medical Society.